Contents

Current Pharmaceutical Design, Volume 11 - Number 30

Editorial [Hot Topic: Novel Factor Xa-and Thrombin-Inhibitors (Executive Editor: Giuseppe G. Nenci)]

, 11(30): 3853 - 3854

Giuseppe G. Nenci


DOI: 10.2174/138161205774580543




Heterogeneity of Synthetic Factor Xa Inhibitors

, 11(30): 3855 - 3876

G. T. Gerotziafas and M. M. Samama


DOI: 10.2174/138161205774580552




Pharmacology and Clinical Potential of Direct Thrombin Inhibitors

, 11(30): 3877 - 3884

L- A. Linkins and J. I. Weitz


DOI: 10.2174/138161205774580598




Direct Thrombin Inhibitors for the Prevention of Venous Thromboembolism after Major Orthopaedic Surgery

, 11(30): 3885 - 3891

G. Agnelli, F. Sonaglia and C. Becattini


DOI: 10.2174/138161205774580615




Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism

, 11(30): 3893 - 3918

A. Iorio, F. Guercini, F. Ferrante and G. G. Nenci


DOI: 10.2174/138161205774580534




Direct Thrombin Inhibitors for the Treatment of Acute Coronary Syndromes and During Percutaneous Coronary Interventions

, 11(30): 3919 - 3929

G. Paoli, P. A. Merlini and D. Ardissino


DOI: 10.2174/138161205774580606




Direct Thrombin Inhibitors for Treatment of Heparin Induced Thrombocytopenia, Deep Vein Thrombosis and Atrial Fibrillation

, 11(30): 3931 - 3941

C. W. Francis


DOI: 10.2174/138161205774580570




Molecular Mechanisms of and Possible Treatment Strategies for Idiopathic Pulmonary Fibrosis

, 11(30): 3943 - 3971

M. Gharaee-Kermani and S. H. Phan


DOI: 10.2174/138161205774580561




Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future

, 11(30): 3973 - 3984

M. Buemi, C. Aloisi, F. Fulvio, C. Caccamo, E. Cavallaro, E. Crasci, M. Criseo, F. Corica and N. Frisina


DOI: 10.2174/138161205774580589




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science